Glycogen Storage Disease Due to Acid Maltase Deficiency
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Glycogen storage disease due to acid maltase deficiency is an early-stage landscape with 8 programs across 7 companies. The most active players are Roche, Glaxo Dba Glaxosmithkline, Prism Pharmaceuticals. 5 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
63%
Small molecule
5 of 8 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)